Log In
BCIQ
Print this Print this
 

DFMO/sulindac, eflornithine/sulindac (CPP-1X/sulindac)

  Manage Alerts
Collapse Summary General Information
Company Cancer Prevention Pharmaceuticals Inc.
DescriptionCombination of eflornithine (difluoromethylornithine, DFMO), a selective inhibitor of ornithine decarboxylase (ODC), and sulindac, a generic NSAID
Molecular Target Ornithine decarboxylase (ODC)
Mechanism of ActionOrnithine decarboxylase (ODC) inhibitor
Therapeutic ModalitySmall molecule: Combination

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$207.5M

0

$190.0M


 Deals Details
Get a free BioCentury trial today